Drug Trial Radar · NCT06411314
Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis
Last checked: Nov 19, 2026Latest source record: May 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Dec 29, 2022
Primary completion
Jul 26, 2023
Study completion Sep 22, 2023
Sponsor
- Lead sponsor
- Avva Rus, JSCIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg vaginal suppositories. The second objective of the study was to investigate the safety of the combination suppositories in the treatment of vulvovaginal candidiasis in non-pregnant adult females.
Conditions
- Vulvovaginal Candidiasis, Genital
Interventions
Natamycin + Lactulose 100 mg + 300 mg vaginal suppositoriesCombination product
1 suppository once daily at bedtime for 6 days
Lactulose 300 mg vaginal suppositoriesDrug
1 suppository once daily at bedtime for 6 days
Pimafucin® (natamycin) 100 mg vaginal suppositoriesDrug
1 suppository once daily at bedtime for 6 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion (%) of patients who achieved a clinical response (recovery) at Visit 2Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Reproductive Medicine and Surgery at the A.I. Evdokimov Moscow State Medical and Dental University
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.